Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

DavosPharma to Market Immunologix’s Antbodies

By R&D Editors | May 10, 2011

Immunologix, Inc., Charleston, S.C., and DavosPharma, Upper Saddle River, N.J. have formed a strategic alliance whereby DavosPharma, a provider of discovery, chemistry, and formulation services, will represent and market 100% human antibodies produced by Immunologix.

Immunologix transforms naïve B-cells to produce 100% human monoclonal antibodies that can target any and all antigens including, cancer, viruses, bacteria, toxins and auto-immune diseases like diabetes, lupus, rheumatoid arthritis and multiple sclerosis. Immunologix collects patient-consented explanted tonsil tissue following tonsillectomies and processes them in its laboratory.

The company holds a worldwide exclusive license from the Medical University of South Carolina, and exclusive U.S. and foreign patents in this technological platform.
“The relationship between Immunologix and DavosPharma has been building since initial discussions began in December of 2010.  We are extremely excited to partner with DavosPharma since they bring an experienced team of experts to Immunologix. 

Together, the companies will offer customers complete transparency. The partnership allows both parties to offer their clients a platform to 100% human monoclonal antibody ready for clinical trials.  It will help in bringing our game changing technology to the pharmaceutical marketplace,” said Dr. Ryan Fiorini.  “This agreement is a win-win for both companies and we are happy to team up with DavosPharma to expand our capabilities.”  

Barry Robins emphasized, “The Immunologix platform of technology offers a new paradigm for therapeutic antibody discovery, development, and manufacturing. Our customers will understand that the ability to identify and produce a 100% human monoclonal antibody in less than 6 months with less adverse side effects is an extremely significant differentiator. The technology that we now offer through this strategic alliance will have an immediate impact on shorter development times, costs, and reduction of adverse effects due to immunogenicity which often derail therapeutic antibody programs. Many of our existing clients will be very interested in adopting this technology.”

Release Date: May 9, 2011
Sources: DavosPharma    Immunologix 

Related Articles Read More >

2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE